AbCellera Biologics price to sales ratio ABCL

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 54.8×
5-year median: 23.9×
Against its 5-year history: 97th; percentile: 0 is its lowest day, 100 its highest
5-year range: 4.0× to 66.0×
Peer median: 3.5×

AbCellera Biologics' price to sales ratio is 54.8× as of Oct 23, 2026.

That is above its 5-year median of 23.9×, higher than on 97% of days in the last 5 years.

Over that time it ranged from 4.0× in Apr 2023 to 66.0× in Jul 2025.

The median for 10 large drugmakers of a similar size is 3.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	54.8×	13.2×	63.7×
2025	30.3×	21.6×	66.0×
2024	26.8×	21.3×	38.9×
2023	32.9×	4.0×	32.9×
2022	4.8×	4.2×	7.7×

Against its peers

Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.

Company	Price to sales ratio
ABCLAbCellera Biologics	54.8×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
INDVIndivior Pharmaceuticals	3.1×
NRIXNurix Therapeutics	3.9×
PBHPrestige Consumer Healthcare	2.0×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
HRMYHarmony Biosciences	2.2×
AMRXAmneal Pharmaceuticals	2.1×
Peer median	3.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on AbCellera Biologics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.